Phathom Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Phathom Pharmaceuticals, Inc.'s operations generated −$167m of cash; it spent $229,000 on capital projects, leaving free cash flow of −$167m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Phathom Pharmaceuticals, Inc.: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	−147	−138	−267	−167	−21
Depreciation and amortisation	1	1	1	1	0
Stock-based pay	24	45	24	29	24
Capital spending	1	2	0	0	0
Free cash flow	−148	−139	−267	−167	−21
Free cash flow after stock pay	−172	−184	−291	−196	−45
Shares issued	—	14	—	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Phathom Pharmaceuticals, Inc.: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	−63	−85	−63	−14	−5	−16	−2	2
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	7	6	8	9	6	6	7	6
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−63	−85	−63	−14	−5	−16	−2	2
Free cash flow after stock pay	−70	−90	−71	−23	−11	−21	−9	−4

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PHAT vs PTGX PHAT vs SNDX LGND vs PHAT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Phathom Pharmaceuticals, Inc.